Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.

MLA

Narongroeknawin, Pongthorn, et al. “Drug Survival and Reasons for Discontinuation of the First Biological Disease Modifying Antirheumatic Drugs in Thai Patients with Rheumatoid Arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization Registry.” International Journal of Rheumatic Diseases, vol. 21, no. 1, Jan. 2018, pp. 170–78. EBSCOhost, https://doi.org/10.1111/1756-185X.12937.

APA

Narongroeknawin, P., Chevaisrakul, P., Kasitanon, N., Kitumnuaypong, T., Mahakkanukrauh, A., Siripaitoon, B., & Katchamart, W. (2018). Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry. International Journal of Rheumatic Diseases, 21(1), 170–178. https://doi.org/10.1111/1756-185X.12937

Chicago

Narongroeknawin, Pongthorn, Parawee Chevaisrakul, Nuntana Kasitanon, Tasanee Kitumnuaypong, Ajanee Mahakkanukrauh, Boonjing Siripaitoon, and Wanruchada Katchamart. 2018. “Drug Survival and Reasons for Discontinuation of the First Biological Disease Modifying Antirheumatic Drugs in Thai Patients with Rheumatoid Arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization Registry.” International Journal of Rheumatic Diseases 21 (1): 170–78. doi:10.1111/1756-185X.12937.